NOVARTIS AG : UBS reiterates its Neutral rating
July 18, 2023 at 06:42 am EDT
In a research note, UBS analyst Michael Leuchten has maintained his recommendation on the stock with a Neutral rating. The target price is unchanged and still at CHF 99.
© MarketScreener with dpa-AFX Analyser - 2023